Clinical Endocrinology (1987), **26**, 743–748

Author Index to Volume 26

ADAMS, C.B.T. see Bevan, J.S.
ADAMS, J. see Polson, D.W., also Stead, R.J.
AGHINI-LOMBARDI, F. see Martino, E.
AKAMIZU, T., MORI, T., KASAGI, K., KOSUGI, S., MIYAMOTO, M., NISHINO, K., SUGAWA, H., YOKOTA, T., NAKAMURA, H., KONISHI, J. and IMURA, I. Anti-TSH antibody with high specificity to human TSH in sera from a patient with Graves' disease: its isolation from, and interaction with, TSH receptor antibodies, 311
ALBERT, J. see Geller, J.
AL-DAMLUJI, S., CUNNAH, D., PERRY, L., GROSSMAN, A. and BESSER, G.M. The effect of alpha adrenergic manipulation on the 24 hour pattern of cortisol secretion in man, 61
AL-DAMLUJI, S., IVESON, T., THOMAS, J.M., PENDLEBURY, D.J., REES, L.H. and BESSER, G.M. Food-induced cortisol secretion is mediated by central alpha-1 adrenoceptor modulation of pituitary ACTH secretion, 629
ALEXANDER, W.D. see McCruden, D.C.
ANDERSEN, O.O. see Ellemann, K.
ANDERSON, P. see Chapman, C.E.
ARCHAMBEAUD-MOUVEROUX, F. see Kuhn, J.M.
ARNOTT, R.D. see Stockigt, J.R.
ASA, S.L. see George, S.R.
ASBURY, J. see Connell, J.M.C.
ASPLUND, K. see Hägg, E.
ATKINSON, A.B. see DALZELL, G.W.
AYERS, B. see Macleod, A.F.
AZZARITO, C. see Valcavi, R.

BAIRD, D.T. see Glasier, A., also West, C.P.
BAMBINI, G. see Martino, E.
BARKAN, A. see Nippoldt, T.B.
BARLOW, J.W. see Mohr, V.S., also Stockigt, J.R.
BARTALENA, L. see Martino, E.
BARUZZI, A. see Lugaresi, A.
BATTEN, J.C. see Stead, R.J.
BAYLIS, P.H. see Fisher, B.M.
BENNER R. see van Ouwerkerk, B.M.
BENRAAD, TH.J. see Hermus, A.R.M.M.
BERGHOUT, A., WIERSINGA, W.M., SMITS, N.J. and TOUBER, J.L. Determinants of thyroid volume as measured by ultrasonography in healthy adults in a non-iodine deficient area, 273
BERGH, T. see Rasmussen, C.
BERRY, C.C. see Geller, J.
BESSER, G.M. see Al-Damluji, S., also Ross, R.J.M.
BEVAN, J.S., ADAMS, C.B.T., BURKE, C.W., MORTON, K.E., MOLYNEUX, A.J., MOORE, R.A. and ESIRI, M.M. Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy, 541
BILLAUD, L. see Kuhn, J.M.
BINDER, C. see Ellemann, K.
BLICHERT-TOFT, M. see McLachlan, S.M.
BLOOM, S.R. see Sandler, L.M.
BORGES, F. see Ross, R.J.M.
BOSCARO, M. see Fallo, F.
BOS, G. see van Ouwerkerk, B.M.
BOYLE, I.T. see Ralston, S.H.
BRADWELL, A.R. see Chapman, C.E.
BRAVERMAN, L.E. see Martino, E.
BROWNELL, J. see Rasmussen, C.
BURGE, J.R. see Burman, K.D.
BURKE, C.B.T. see Bevan, J.S.
BURMAN, K.D., SMALLRIDGE, R.C., BURGE, J.R., O'BRIAN, J.T. and WARTOFSKY, L. Iodide administration enhances thyrotrophin responsiveness to thyrotrophin-releasing hormone during fasting: evidence for normal pituitary feedback, 9
BURRIN, J.M. see Lacoumenta, S., also Sandler, L.M.
BURROW, G.N. see George, S.R.
BURT, A.D. see Connell, J.M.C.
BUTLER, J. see Cundy, T.

CACCIARI, E. see Lugaresi, A.
CARR, D. see McLachlan, S.M.
CARR, D.H. see Sandler, L.M.
CARSON, D.J. see Dalzell, G.W.
CECCARELLI, C. see Martino, E.
CHANDLER, S.T. see Chapman, C.E.
CHAPMAN, C.E., FAIRWEATHER, D.S., KEELING, A.A., CHANDLER, S.T., ANDERSON, P., DYKES, P.W. and BRADWELL, A.R. An evaluation of anti-insulin radioimmunodetection in patients with suspected insulinoma, 433
CHENG, R.W. see Polson, D.W.
CHRISTIANSEN, C. see Kristiansen, J.H., also Riis, B.J.
CLARK, F. see McLachlan, S.M.
CLAYTON, R.N. Gonadotrophin releasing hormone: from physiology to pharmacology, 361
CONNELL, J.M.C., CORDER, R., ASBURY, J., MACPHERSON, S., INGLIS, G.C., LOWRY, P., BURT,

A.D. and SEMPLE, P.F. Neuropeptide Y in multiple endocrine neoplasia: release during surgery for phaeochromocytoma, 75
CONNELL, J.M.C. see MCCRUDEN, D.C.
CORDER, R. see Connell, J.M.C.
CORTELLI, P. see Lugaresi, A.
COWAN, R.A. see Ralston, S.H.
CROSS, E.G. see George, S.R.
CUNDY, T., HAINING, S.A., GUILLAND-CUMMING, D.F., BUTLER, J. and KANIS, J.A. Remission of hypoparathyroidism during lactation: evidence for a physiological role for prolactin in the regulation of vitamin D metabolism, 667
CUNEO, R.C., LIVESEY, J.H., NICHOLLS, M.G., ESPINER, E.A. and DONALD, R.A. Effects of alpha-1 adrenergic blockade on the hormonal response to hypoglycaemic stress in normal man, 1
CUNNAH, D. see Al-Damluji, S.

DALZELL, G.W., ATKINSON, A.B., CARSON, D.J. and SHERIDAN, B. Normal growth and pubertal development during bromocriptine treatment for a prolactin-secreting pituitary macroadenoma, 169
DATE, J. see McLachlan, S.
DAVIDSON, J.K. see Herd, G.W.
DAVIES, T.F. see Piccinini, L.A.
DE HAAN, J. see Hamilton, C.J.C.M.
DE JONG, F.H. see Lamberts, S.W.J.
DEMURA, H. see Sakurai, H.
DIEGUEZ, C. see Page, M.D., also Valcavi, R.
DOBSON S.H. see White, A.
DOCTER, R. see an Ouwerkerk, B.M.
DONALD, R.A. see Cuneo, R.C.
DOTTI, C. see Valcavi, R.
DUNGER, D.B. see Seckl, J.R.
DYKES, P.W. see Chapman, C.E.

EDWARDS, C.A. see Page, M.D., also Valcavi, R.
ELLEMANN, K., THORSTEINSSON, B., FUGLEBERG, S., FELDT-RASMUSSEN, B., ANDERSEN, O.O., GRONBAEK, P. and BINDER, C. Kinetics of insulin disappearance from plasma in cortisone-treated normal subjects, 623
ESIRI, M.M. see Bevan, J.S.
ESPINER, E.A. and NICHOLLS, M.G. Human atrial natriuretic peptide, 637
ESPINER, E.A. see Cuneo, R.C.
EVANS, D.J. see Ng, L.L.
EVANS, P.J., WOODHEAD, J.S., WEEKS, I. and SCANLON, M.F. Circulating TSH levels measured with an immunochemiluminometric assay in patients taking drugs interfering with biochemical thyroid status, 717
EVERS, J.L.H. see Hamilton, C.J.C.M.

FACHNIE, J.D. see Jackson, J.A.
FAIRWEATHER, D.S. see Chapman, C.E.
FALLO, F., BOSCARO, M., SONINO, N. and MANTERO, F. Effects of naloxone on the pituitary-adrenal axis in patients with dexamethasone-suppressible hyperaldosteronism, 163
FARNDON, J.R. see Steel, N.R.
FAVRE, L. and VALLOTON, M.B. Influence of nifedipine and enalapril on osmoregulation of vasopressin, 25
FAY, W. see Geller, J.
FELDT-RASMUSSEN, B. see Ellemann, K.
FELDT-RASMUSSEN, U. see McLachlan, S.M.
FISHER, B.M., BAYLIS, P.H. and FRIER, B.M. Plasma oxytocin, arginine vasopressin and atrial natriuretic peptide responses to insulin-induced hypoglycaemia in man, 179
FORESTA, C., INDINO, M. and SCANDELLARI, C. Role of gonadal steroids in the serotoninergic control of prolactin secretion in men, 601
FRANKS, S. see Polson, D.W.
FRASER, R. see Herd, G.W., also Isles, C.G.
FRASER, W.D. see Ralston, S.H.
FRIER, B.M. see Fisher, B.M.
FRÖLICH, M. see Roelfsema, F.
FUGLEBERG, S. see Ellemann, K.
FUJISHIMA, M. see Yoshinari, T.

GAMBACCIANI, M., LIU, J.H., SWARTZ, W.H., TUEROS, V.S., RASMUSSEN, D.D. and YEN, S.S.C. Intrinsic pulsatility of ACTH release from the human pituitary *in vitro*, 557
GANCEL, A. see, Kuhn, J.M.
GARDNER, M.D. see Ralston, S.H.
GELLER, J., LIU, J., ALBERT, J., FAY, W., BERRY, C.C. and WEIS, P. Relationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone level, 155
GEORGE, S.R., KOVACS, K., ASA, A.L., HORVATH, E., CROSS, E.G. and BURROW, G.N. Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma, 395
GIBBS, J.T. see Page, M.D.
GINSBERG, J., RAFTER, D.J., VON WESTARP, C. and MURRAY, P.G. The effects of dithiothreitol on thyroid stimulation *in vitro*, 417
GLASIER, A., BAIRD, D.T. and MCNEILLY, A.S. Evidence for gonadal desentization after pulsatile therapy in women with amenorrhoea? 441
GRONBAEK, P. see Ellemann, K.
GROSSMAN, A. see Al-Damluji, S., also Ross, R.J.M.
GUILLAND-CUMMING, D.F. see Cundy, T.

HÄGG, E., ASPLUND, K. and LITHNER, F. Value of

basal plasma cortisol assays in the assessment pituitary-adrenal insufficiency, 221
HAINING, S.A. see Cundy, T.
HALL, G.M. see Lacoumenta, S.
HALL, R. see Page, M.D.
HAMBLIN, P.S. see Newnham, H.H.
HAMILTON, C.J.C.M., EVERS, J.L.H. and DE HAAN, J. Ovulatory disturbances in patients with luteal insufficiency, 129
HENNEMANN, G. see van Ouwerkerk, B.M.
HERD, G.W., SEMPLE, P.F., PARKER, D., DAVIDSON, J.K.. HILDITCH, T.E. and FRASER, R. False localization of an aldosteronoma by dexamethasone-suppressed adrenal scintigraphy, 699
HERMUS, A.R.M.M., PIETERS, G.F.F.M., PESMAN, G.J., HOFMAN, J., SMALS, A.G.H., BENRAAD, TH.J. and KLOPPENBORG, P.W.C. Escape from dexamethasone-induced ACTH and cortisol suppression by corticotrophin-releasing hormone: modulatory effect of basal dexamethasone levels, 67
HIGASHIDA, T. see Sakurai, H.
HILDITCH, T.E. see Herd, G.W., also McCruden, D.C.
HOADLEY, M. see White, A.
HODGINS, M.B. see Wilson, S. C.
HODSON, M.E. see Stead, R.J.
HOFMAN, J. see Hermus, A.R.M.M.
HOLCOMBE, M. see Steel, N.R.
HOLMAN, R.R. see Turner, R.C.
HORVATH, E. see George, S.R.
HOWLETT, T.A. Hormonal responses to exercise and training: a short review, 723
HUEN, K. see Seckl, J.R.

IMURA, H. see Akamizu, T.
INAGAMI, T. see Sakurai, H.
INDINO, M. see Foresta, C.
INGLIS, G.C. see Connell, J.M.C.
INOUE, K. see Yoshinari, M.
ISLES, C.G., MACDOUGALL, I.C., LEVER, A.F. and FRASER, R. Hypermineralocorticoidism due to adrenal carcinoma: plasma corticosteroids and their response to ACTH and angiotensin II, 239
ISOTALO, H. see Kauppila, A.
ITATANI, H. SEE NAMIKI, M.
IVESON, T. SEE AL-DAMLUJI, S.

JACKSON, J.A., RAJU, B.U., FACHNIE, J.D., MELLINGER, R.C., JANAKIRAMAN, N., LLOYD R.V. and VINIK, A.I. Malignant somatostatinoma presenting with diabetic ketoacidosis, 609
JACOBS, H.S. see Stead, R.J.
JAMES, V.H.T. see Polson, D.W.
JANAKIRAMAN, N. see Jackson, J.A.
JENSEN, J. see Riis, B.J.
JENSEN, J.T. see Kristiansen, J.H.
JOHANSEN, J. see Kristiansen, J.H.
JOLY, J. see Kuhn, J.M.
JOPLIN, G.F. see Sandler, L.M.

KANIS, J.A. see Cundy, T.
KASAGI, K. see Akamizu, T.
KATO, K. see Yoneda, M.
KAUPPILA, A. ISOTALO, H., KIRKINEN, P., MÄKILÄ, U-M., ORAVA, M. and VIHKO, R. Metoclopramide-induced hyperprolactinaemia: effects on corpus luteum function, endometrial steroid receptor concentrations and 17β-hydroxysteroid dehydrogenase activity, 145
KEELING, A.A. see Chapman, C.E.
KEHLET, H. see Lindholm, J.
KELCH, R.P. see Nippoldt, T.B.
KENDALL-TAYLOR, P. see Steel, N.R.
KHOURY, S. see Nippoldt, T.B.
KIDDY, D. see Polson, D.W.
KIRKINEN, P. see Kauppila, A.
KLIJN, J.G.M. see Lamberts, S.W.J.
KLOPPENBORG, P.W.C. see Hermus, A.R.M.M.
KONISHI, J. see Akamizu, T.
KOPPESCHAAR, H.P.F. see Page, M.D.
KOSUGI, S. see Akamizu, T.
KOVACS, K. see George, S.R.
KRENNING, E.P. see van Ouwerkerk, B.M.
KRISTIANSEN, J.H., RØDBRO, P., CHRISTIANSEN, C., JOHANSEN, J. and JENSEN, J.T. Familial hypocalciuric hypercalcaemia III: bone mineral metabolism, 713
KUHN, J.M., MAHOUDEAU, J.A., BILLAUD, L., JOLY, J., RIEU, M., GANCEL, A., ARCHAMBEAUD-MOUVEROUX, F., STEG, A. and LUTON, J.P. Evaluation of diagnostic criteria for Leydig cell tumours in adult men revealed by gynaecomastia, 407
KURIMOTO, F. see Sakurai, H.

LACOUMENTA, S., YEO, T.H., BURRIN, J.M. and HALL, G.M. Beta-endorphin infusion fails to modulate the hormonal and metabolic responses to surgery, 657
LAMBERTS, S.W.J., KLIJN, J.G.M. and DE JONG, F.H. The definition of true recurrence of pituitary-dependent Cushing's syndrome after transsphenoidal operation, 707
LENZIARDI, M. see Martino, E.
LEVER, A.F. see Isles, C.G.
LEVER, E.G., TROSSER, A. and SMITH, C. Cardiovascular and hormonal responses to thyrotrophin releasing hormone in acromegalics, 521
LIGHTMAN, S.L. see Seckl, J.R.
LIM, C-F. see Newnham, H.H., also Stockigt, J.R.
LINDHOLM, J. and KEHLET, H. Re-evaluation of the clinical value of the 30 min ACTH test in assessing

the hypothalamic-pituitary-adrenocortical function, 53
LITHNER, F. see Hägg, E.
LIU, J. see Geller, J.
LIU, J.H. see Gambacciani, M.
LIVESEY, J.H. see Cuneo, R.C.
LLOYD, R.V. see JACKSON, J.A.
LONG, F. see Newnham, H.H.
LOWRY, P. see Connell, J.M.C.
LUGARESI, A., BARUZZI, A., CACCIARI, E., CORTELLI, P., MEDORI, R., MONTAGNA, P., TINUPER, P., ZUCCONI, M., ROITER, I. and LUGARESI, E. Lack of vegetative and endocrine circadian rhythms in fatal familial thalamic degeneration, 573
LUGARESI, E. see Lugaresi, A.
LUTON, J.P. see Kuhn, J.M.

MACDOUGALL, I.C. see Isles, C.G.
MACLEOD, A.F., AYERS, B., YOUNG, A.E., MUDD, W.E. and SÖNKSEN, R.H. Resolution of hypergastrinaemia after parathyroidectomy in multiple endocrine neoplasia syndrome type I (MEN type I), 693
MACPHERSON, S. see Connell, J.M.C.
MAHOUDEAU, J.A. see Kuhn, J.M.
MÄKILÄ, U-M. see Kauppila, A.
MANTERO, F. see Fallo, F.
MARIOTTI, S. see Martino, E.
MARSHALL, E. see Ralston, S.H.
MARSHALL, J.C. Nippoldt, T.B.
MARTINO, E., AGHINI-LOMBARDI, F., MARIOTTI, S., BARTALENA, L., LENZIARDI, M., CECCARELLI, C., BAMBINI, G., SAFRAN, M., BRAVERMAN, L.E. and PINCHERA, A. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases, 227
MASON, H.D. see Polson, D.W.
MATSUMOTO, K. see Namiki, M.
MATTHEWS, D.R. see Turner, R.C.
MCCRUDEN, D.C., HILDILTCH, T.E., CONNELL, J.M.C., MCLELLAN, A.R., ROBERTSON, J. and ALEXANDER, W.D. Duration of antithyroid action of methimazole estimated with an intravenous perchlorate discharge test, 33
MCLACHLAN, S.M., FELDT-RASMUSSEN, U., YOUNG, E.T., MIDDLETON, S.L., BLICHERT-TOFT, M., SIERSBOEK-NIELSEN, K., DATE, J., CARR, D., CLARK, F. and REES SMITH, B. IgG subclass distribution of thyroid autoantibodies: a 'fingerprint' of an individual's response to thyroglobulin and thyroid microsomal antigen, 335
MCLELLAN, A.R. see McCruden, D.C.
MCNEILLY, A.S. see Glasier, A.
MEDD, W.E. see Macleod, A.F.
MEDORI, R. see Lugaresi, A.
MELLINGER, R.C. see Jackson, J.A.
MIDDLETON, S.L. see McLachlan, S.M.
MIYAMOTO, M. see Akamizu, T.
MIZUNO, S. see Yoneda, M.
MOHR, V.S., BARLOW, J.W., TOPLISS, D.J., O'DEA, K. and STOCKIGT, J.R. Evaluation of T4 and T3 binding kinetics in the thyroxine binding globulin abnormality of Australian aborigines, 531
MOHR, V.S. see Stockigt, J.R.
MOLYNEUX, A.J. see Bevan, J.S.
MONTAGNA, P. see Lugaresi, A.
MOORE, R.A. see Bevan, J.S.
MORI, T. see Akamizu, T.
MORTON, K.E. see Bevan, J.S.
MURRAY, P.G. see Ginsberg, J.

NABARRO, J.D.N. Acromegaly, 481
NAKAMURA, H. see Akamizu, T.
NAKAMURA, M. see Namiki, M.
NAKASHIMA, T. see Yoshinari, M.
NAMIKI, M., NAKAMURA, M., OKUYAMA, A., SONODA, T., ITATANI, H., SUGAO, H., SAKURAI, T., NISHIMUNE, Y. and MATSUMOTO, K. Reduction of human and rat testicular follicle stimulating hormone receptors by human menopausal gonadotrophin *in vivo* and *in vitro*, 675
NARUSE, K. see Sakurai, H.
NARUSE, M. see Sakurai, H.
NEWNHAM, H.H., HAMBLIN, P.S., LONG, F., LIM, C-F., TOPLISS, D.J. and STOCKIGT, J.R. Effect of oral frusemide on diagnostic indices of thyroid function, 423
NGAHFOONG, L. see Ross, R.J.M.
NG, L.L. and EVANS, D.L. Leucocyte sodium transport in acromegaly, 471
NICHOLLS, M.G. see Cuneo, R.C., also Espiner, E.A.
NIPPOLDT, T.B., KHOURY, S., BARKAN, A., KELCH, R.P. and MARSHALL, J.C. Gonadotrophin responses to GnRH pulses in hypogonadotrophic hypogonadism: LH responsiveness is maintained in the presence of luteal phase concentrations of oestrogen and progesterone, 293
NISHIMUNE, Y. see Namiki, M.
NISHINO, K. see Akamizu, T.

OBANA, K. see Sakurai, H.
O'BRIAN, J.T. see Burman, K.D.
O'DEA, K. see Mohr, V.S.
OISO, Y. see Yoneda, M.
OKAMURA, K. see Yoshinari, M.
OKUYAMA, A. see Namiki, M.
O'RAHILLY, S.P. see Turner, R.C.
ORAVA, M. see Kauppila, A.

PAGE, M.D., KOPPESCHAAR, H.P.F., DIEGUEZ, C.,

GIBBS, J.T., HALL, R., PETERS, J.R. and SCANLON, M.F. Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep-related growth hormone release in young patients with insulin-dependent diabetes mellitus, 355
PAGE, M.D., KOPPESCHAAR, H.P.F., EDWARDS, C.A., DIEGUEZ, C. and SCANLON, M.F. Additive effects of growth hormone releasing factor and insulin hypoglycaemia on growth hormone release in man, 589
PAGE, M.D. see Valcavi, R.
PARKER, D. see Herd, G.W.
PENDLEBURY, D.J. see AL-DAMLUJI, S.
PERRY, L. see Al-Damluji, S.
PESMAN, G.J. see Hermus, A.R.M.M.
PETERS, J.R. see Page, M.D.
PICCININI, L.A., ROMAN, S.H. and DAVIES, T.F. Autoimmune thyroid disease and thyroid cell class II major histocompatibility complex antigens, 253
PIETERS, G.F.F.M. see Hermus, A.R.M.M.
PINCHERA, A. see Martino, E.
POLSON, D.W., MASON, H.D. and FRANKS, S. Bromocriptine treatment of women with clomiphene-resistant polycystic ovary syndrome, 197
POLSON, D.W., MASON, H.D., SALDAHNA, M.B.Y. and FRANKS, S. Ovulation of a single dominant follicle during treatment with low-dose pulsatile follicle stimulating hormone in women with polycystic ovary syndrome, 205
POLSON, D.W., FRANKS, S., REED, M.J., CHENG, R.W., ADAMS, J. and JAMES, V.H.T. The distribution of oestradiol in plasma in relation to uterine cross-sectional area in women with polycystic or multifollicular ovaries, 581
POLDSON, D.W., SAGLE, M., MASON, H.D., KIDDY, D. and FRANKS, S. Recovery of luteal function after interruption of gonadotrophin secretion in the mid-luteal phase of the menstrual cycle, 597
PORTIOLI, I. see Valcavi, R.

RAFTER, D.J. see Ginsberg, J.
RAJU, B.U. see Jackson, J.A.
RALSTON, S.H., COWAN, R.A., GARDNER, M.D., FRASER, W.D., MARSHALL, E. and BOYLE, I.T. Comparison of intestinal calcium absorption and circulating 1,25-dihydroxyvitamin D levels in malignancy-associated hypercalcaemia and primary hyperparathyroidism, 281
RASMUSSEN, C., BERGH, T., WIDE, L. and BROWNELL, J. CV 205–502: a new long-acting drug for inhibition of prolactin hypersecretion, 321
RASMUSSEN, D.D. see Gambacciani, M.
RATCLIFFE, J.G. see White, A.
REED, M.J. see Polson, D.W.
REES, L.H. see Al-Damluji, S., also Ross, R.J.M.
REES SMITH, B. see McLachlan, S.M.
RIEU, M. see Kuhn, J.M.
RIIS, B.J., JENSEN, J. and CHRISTIANSEN, C. Cyproterone acetate, an alternative gestagen in postmenopausal oestrogen/gestagen therapy, 327
ROBERTSON, J. see McCruden, D.C.
RØDBRO, P. see Kriastiansen, J.H.
ROELFSEMA, F., FRÖLICH, M. and VAN DULKEN, H. Somatomedin-C levels in treated and untreated patients with acromegaly, 137
ROITER, I. see Lugaresi, A.
ROMAN, S.H. see Piccinini, L.A.
ROSS, R.J.M., BORGES, F., GROSSMAN, A., SMITH, R., NGAHFOONG, L., REES, L.H., SAVAGE, M.O. and BESSER, G.M. Growth hormone pretreatment in man blocks the response to growth hormone-releasing hormone: evidence for a direct effect of growth hormone, 117
RUDENSKI, A.S. see Turner, R.C.

SAFRAN, M. see Martino, E.
SAGLE, M. see Polson, D.W.
SAKURAI, H., NARUSE, M., NARUSE, K., OBANA, K., HIGASHIDA, T., KURIMOTO, F., DEMURA, H., INAGAMI, T. and SHIZUME, K. Postural suppression of plasma atrial natriuretic polypeptide concentrations in man, 173
SAKURAI, T. see Namiki, M.
SALDAHNA, M.B.Y. see Polson, D.W.
SANDLER, L.M., BURRIN, J.M., WILLILAMS, G., JOPLIN, G.F., CARR D.H. and BLOOM, S.R. Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995), 85
SAVAGE, M.O. see Rees, R.J.M.
SCANDELLARI, C. see Foresta, C.
SCANLON, M.F. see Evans, P.J., also Page, M.D., also Valcavi, R.
SCOTT, J.S. see Wilson, S.C.
SECKL, J.R., DUNGER, D.B., HUEN, K. and LIGHTMAN, S.L. The plasma arginine vasopressin response to insulin-induced hypoglycaemia in children with short stature is related to age and the onset of puberty, 347
SEMPLE, P.F. see Connell, J.M.C., also Herd, G.W.
SHERIDAN, B. see Dalzell, G.W.
SHIROOZU, A. see Yoshinari, M.
SHIZUME, K. see Sakurai, H.
SIERSBOEK-NIELSEN, K. see McLachlan, S.M.
SIETNIEKS, A. see Wilton, P.
SMALLRIDGE, R.C. see Burman, K.D.
SMALS, A.G.H. see Hermus, A.R.M.M.
SMITH, C. see Lever, E.G.
SMITH, H. see White, A.
SMITH, R. see Ross, R.J.M.
SMITS, N.J. see Berghout, A.

Sonino, N. see Fallo, F.
Sönksen, R.H. see Macleod, A.F.
Sonoda, T. see Namiki, M.
Stead, R.J., Hodson, M.E., Batten, J.C., Adams, J. and Jacobs, H.S. Amenorrhoea in cystic fibrosis, 187
Steel, N.R., Taylor, J.J., Young, E.T., Farndon, J.R., Holcombe, M. and Kendall-Taylor, P. The effect of subtotal thyroidectomy with propranolol preparation of antibody activity in Graves' disease, 97
Steg, A. see Kuhn, J.M.
Stockigt, J.R., Lim, C-F., Topliss, D.J., Arnott, R.D., Mohr, V.S. and Barlow, J.W. Anomalous binding characteristics of human thyroxine binding globulin due to a dilution-dependent separation artefact, 565
Stockigt, J.R. see Mohr, V.S., also Newnham, H.H.
Sugao, H. see Namiki, M.
Sugawa, H. see Akamizu, T.
Swartz, W.H. see Gambacciani, M.

Takatsuki, K. see Yoneda, M.
Taylor, J.J. see Steel, N.R.
Thomas, J.M. see Al-Damluji, S.
Thorsteinsson, B. see Ellemann, K.
Tinuper, P. see Lugaresi, A.
Tomita, A. see Yoneda, M.
Topliss, D.J. see Mohr, V.S., also Newnham, H.H., also Stockigt, J.R.
Touber, J.L. see Berghout, A.
Trosser, A. see Lever, E.G.
Tueros, V.S. see Gambacciani, M.
Turner, R.C., Rudenski, A.S., Holman, R.R., Matthews, D.R. and O'Rahilly, S.P. Quantitative modelling of endocrine diseases as exemplified by diabetes, 107

Valcavi, R., Dieguez, C., Azzarito, C., Edwards, C.A., Dotti, C., Page, M.D., Portioli I. and Scanlon, M.F. Effect of oral administration of melatonin on GH responses to GRF $_{1-44}$ in normal subjects, 453
Valloton, M.B. see Favre, L.
Van Dulken, H. see Roelfsema, F.
Van Oudenaren, A. see van Ouwerkerk, B.M.
Van Ouwerkerk, B.M., Krenning, E.P., Docter, R., Bos, G., Van Oudenaren, A., Benner, R. and Hennemann, G. Cellular and humoral immunity in patients with hyperthyroid Graves' disease before, during and after antithyroid drug treatment, 385
Vaughan Williams, C.A. Hypothalamic function in women with secondary hypogonadism and unresponsive to clomiphene therapy, 17
Vihko, R. see Kauppila, A.
Vinik, A.I. see Jackson, J.A.
Von Westarp, C. see Ginsberg, J.

Wartofsky, L. see Burman, K.D.
Weeks, I. see Evans, P.J.
Weis, P. see Geller, J.
West, C.P. and Baird, D.T. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue, 213
White, A., Smith, H., Hoadley, M., Dobson, S.H. and Ratcliffe, J.G. Clinical evaluation of a two-site immunoradiometric assay for adrenocorticotrophin in unextracted human plasma using monoclonal antibodies, 41
Wide, L. see Rasmussen, C.
Wiersinga, W.M. see Berghout, A.
Williams, G. see Sandler, L.M.
Wilson, S.C., Hodgins, M.B. and Scott, J.S. Incomplete masculinization due to a deficiency of 17β-hydroxysteroid dehydrogenase: comparison of prepubertal and peripubertal siblings, 459
Wilton, P. and Sietnieks, A. An open-labelled study of the safety, acute metabolic activity and pharmacokinetic profile of a short-term course of recombinant human growth hormone in healthy volunteers, 125
Woodhead, J.S. see Evans, P.J.

Yamauchi, K. see Yoneda, M.
Yen, S.S.C. see Gambacciani, M.
Yeo, T.H. see Lacoumenta, S.
Yokota, T. see Akamizu, T.
Yoneda, M., Takatsuki, K., Yamauchi, K., Oiso, Y., Tomita, A., Mizuno, S. and Kato, K. Determinants of enolase isozymes in various adrenal gland tumours, 303
Yoshinari, M., Okamura, K., Shiroozu, A., Nakashima, T., Inoue, K. and Fujishima, M. Acid thyroglobulin protease activities in human diseased thyroid glands, 685
Young, A.E. see Macleod, A.F.
Young, E.T. see McLachlan, S.M., also Steel, N.R.

Zucconi, M. see Lugaresi, A.

Clinical Endocrinology (1987), **26**, 749–752

Subject Index to Volume 26

ACTH
  and alpha-1 adrenoceptors in hypoglycaemia, 1
  and effect of dexamethasone, 67
  pulsatile pituitary release, 557
  evaluation of a two-site immunoradiometric assay for, 41
ACTH test
  30 min, in assessing hypothalamic-pituitary-adrenocortical function, 53
Acid protease activity
  and diseased thyroid glands, 685
Acromegaly
  and treatment with long-acting somatostatin analogue (SMS 201–994), 85
  and somatomedin-C levels, 137
  and responses to TRH in, 521
  and leucocyte sodium transport, 471
Adrenal carcinoma
  and hypermineralocorticoidism, 239
Adrenal gland
  and enolase isozymes in tumours, 303
Adrenocortical insufficiency
  and basal plasma cortisol assays, 221
Aldosteronism
  and dexamethasone-suppressed adrenal scintigraphy, 699
Alpha-1 adrenoceptor
  and mediation of cortisol secretion, 629
  and ACTH in hypoglycaemia, 1
  and cortisol secretion, 61
Amenorrhoea
  in cystic fibrosis, 187
  and gonadal desensitization after pulsatile therapy, 441
Amiodarone
  and iodine-induced hypothyroidism, risk factors, 227
  iodine-induced hypothyroidism, risk factors and follow-up in 28 cases, 227
Anti-insulin radioimmunodetection
  evaluation in suspected insulinoma, 433
Antithyroid drug treatment
  and immunity in Graves' disease, 385
Anti-TSH antibody
  in Graves' disease, and TSH receptor antibodies, 311
Arginine vasopressin
  and hypoglycaemia in children, 347
Atrial natriuretic peptide
  effect of posture on, 173
  and insulin-induced hypoglycaemia, 179
  review, 637
Australian aborigines
  and thyroxine binding globulin abnormality, 531
Autoimmune thyroid disease
  and thyroid cell class II MHC antigens, 253

β-endorphin
  and hormonal and metabolic response to surgery, 657
Bone mineral metabolism
  and familial hypocalciuric hypercalaemia, 713
Bromocriptine
  treatment for a prolactin-secreting pituitary macroadenoma, 169
  and polycystic ovary syndrome, 197
  and surgery for pituitary tumour, 541

Calcium absorption
  and circulating 1,25-dihydroxyvitamin D in hypercalcaemia and hyperparathyroidism, 281
Cholinergic blockade
  and nocturnal GH release in diabetes mellitus, 355
Circadian rhythms
  and familial thalamic degeneration, 573
Clomiphene
  and secondary hypogonadism, 17
Corpus luteum function
  effect of induced hyperprolactinaemia, 145
Corticotrophin-releasing hormone
  effect of pretreatment with dexamethasone, 67
Cortisol
  and effect of dexamethasone, 67
Cortisol assays
  in the assessment of pituitary-adrenal insufficiency, 221
Cortisol secretion
  effect of alpha adrenergic manipulation on, 61
  and alpha-1 adrenoceptor mediation of pituitary ACTH secretion, 629
Cortisone
  effect on insulin kinetics, 623
CV 205–502
  a new long-acting prolactin inhibitor, 321
Cyproterone acetate
  and postmenopausal bone loss, 327
Cystic fibrosis
  and amenorrhoea, 187

Delayed puberty
and bromocriptine in prolactin-secreting pituitary macroadenomas, 169
Dexamethasone
effect on corticotrophin-releasing hormone, ACTH and cortisol suppression, 67
Dexamethasone-suppressible hyperaldosteronism
effects of naloxone, 163
Dexamethasone-suppressed adrenal scintigraphy
and false localization of an aldosteronoma, 699
Diabetes
an example of quantitative modelling in endocrine diseases, 107
Diabetes mellitus
and cholinergic blockade of nocturnal GH release, 355
Diabetic ketoacidosis
and somatostatinoma, 609
Dihydrotestosterone
and human prostatic epithelial cell protein synthesis, 155
1,25-Dihydroxyvitamin D
and calcium absorption in cancer hypercalcaemia, 281
Dithiothreitol
effects on thyroid stimulation, 417

Enalapril
and osmoregulation of vasopressin, 25
Endometrial steroid receptors
effect of induced hyperprolactinaemia, 145
Enolase isozymes
in adrenal tumours, 303
Exercise
hormonal responses to, 723

FSH
low-dose pulsatile treatment in polycystic ovary syndrome, 205
FSH receptors
testicular, and hMG, 675
Familial hypocalciuric hypercalcaemia
bone mineral metabolism, 713
Fasting
TSH levels and TRH responsiveness during, 9

GH
evidence for a direct effect on own secretion, 117
safety and short-term biological effects of recombinant human GH, 125
and cholinergic blockade of nocturnal release in diabetes mellitus, 355
responses to GRF_{1-44} after melatonin, 453
GH cell adenoma
effect on somatostatin analogue SMS 210–995, 395
GH release
additive effects of GRF and hypoglycaemia, 589
GHRH
effect of pretreatment with GH, 117
GnRH
physiology and pharmacology, 361
GnRH pulses
and LH in hypogonadotrophic hypogonadism, 293
GRF_{1-44}
and GH responses after melatonin, 453
and hypoglycaemia on GH release, 589
Gonadal desensitization
after pulsatile therapy in amenorrhoea, 441
Gonadal steroids
and serotoninergic control of prolactin secretion, 601
Gonadotrophin secretion
and luteal function in the menstrual cycle, 597
Graves' disease
anti-TSH antibody and interaction with TSH receptor antibodies, 311
effect of subtotal thyroidectomy with propanolol, 97
immunity after antithyroid drug treatment, 385
Gynaecomastia
caused by Leydig cell tumours, 407

hMG
and testicular FSH receptors, 675
Hormones
response to exercise and training, 723
Human atrial natriuretic peptide, 637
Human leucocyte antigen
and autoimmune thyroid disease, 253
17β-Hydroxysteroid dehydrogenase activity
effect of induced hyperprolactinaemia, 145
17β-Hydroxysteroid dehydrogenase deficiency
and incomplete masculinization, 459
Hyperaldosteronism
and naloxone, 163
Hypercalcaemia
calcium absorption and 1,25-dihydroxyvitamin D, 281
Hypergastrinaemia
and parathyroidectomy in MEN type I, 693
Hypermineralocorticoidism
due to adrenal carcinoma, 239
Hyperparathyroidism
calcium absorption and 1,25-dihydroxyvitamin D, 81
Hyperprolactinaemia
metoclopramide-induced, effects on menstrual cycle, 145
Hypoglycaemia
effect of alpha-1 adrenergic blockade in, 1

and GRF, effect on GH release, 589
effect on plasma oxytocin, plasma vasopressin and atrial natriuretic peptides, 179
and arginine vasopressin in children with short stature, 347
Hypogonadism
hypothalamic function and clomiphene, 17
Hypoparathyroidism
and vitamin D metabolism during lactation, 667
Hypothalamic function
and clomiphene, 17
Hypothyroidism
amiodarone iodine-induced, 227

IgG subclasses of thyroid autoantibodies, 335
Immunity
and antithyroid drug treatment in Graves' disease, 385
Immunochemiluminometric assay
and measurement of circulating TSH levels, 717
Immunoradiometric assay
for ACTH in unextracted human plasma, 41
Incomplete masculinization
and 17 β-hydroxysteroid dehydrogenase deficiency, 459
Insulin hypoglycaemia test
compared to the 30 min ACTH test, 53
Insulin-induced hypoglycaemia
effect on plasma oxytocin, plasma vasopressin and atrial natriuretic peptide, 179
Insulin kinetics
effect of cortisone, 623
Insulinoma
evaluation of anti-insulin scanning, 433
Iodide
effect during fasting, evidence of pituitary feedback regulation, 9

LH
responses to GnRH in hypogonadotrophic hypogonadism, 293
LHRH agonist (Zoladex depot)
and suppression of ovarian activity, 213
Lactation
and hypoparathyroidism, 667
Leucocyte sodium transport
in acromegaly, 471
Leydig cell tumours
evaluation of diagnostic criteria for, 407
Luteal function
and gonadotrophin secretion in the menstrual cycle, 597
Luteal insufficiency
ovulatory disturbances in patients with, 129

Major histocompatibility complex antigens
and autoimmune thyroid disease, 253
Melatonin
effect on GH responses to GRF_{1-44}, 453
Menstrual cycle
and luteal function, 597
MEN type I
hypergastrinaemia after parathyroidectomy in, 693
Methimazole
estimation of duration of antithyroid effect, 33
Multifollicular ovary
and oestradiol distribution, 581

Neuropeptide Y
presence in multiple endocrine neoplasia and phaeochromocytoma, 75
Nifedipine
and osmoregulation of vasopressin, 25

Oestradiol distribution
in relation to uterine cross-sectional area, 581
Oral frusemide
and thyroid function, 423
Ovarian activity
suppression by long-acting LHRH agonist (Zoladex depot), 213
Ovulation
in polycystic ovary syndrome, treatment with FSH, 205
Ovulatory disturbances
and luteal insufficiency, 129
Oxytocin
and insulin-induced hypoglycaemia, 179

Phaeochromocytoma
and presence of neuropeptide Y, 75
Pirenzepine
effect on nocturnal GH release in diabetes mellitus, 355
Pituitary
and pulsatile ACTH release, 557
Pituitary feedback regulation
and fasting, 9
Pituitary-dependent Cushing's syndrome
true recurrence after transsphenoidal surgery, 707
Pituitary tumour
effect of surgery and bromocriptine therapy, 541
Polycystic ovary
and oestradiol distribution, 581
Polycystic ovary syndrome
and treatment with pulsatile FSH, 205
bromocriptine treatment in, 197
Postmenopausal bone loss
and cyproterone acetate, 327
Prolactin inhibitor
CV 205–502, a new long-acting drug, 321
Prolactin-secreting pituitary macroadenomas
normal growth and pubertal development during bromocriptine therapy, 169

Prolactin secretion
role of gonadal steroids in serotoninergic control, 601
Propanolol
effect on antibody activity in Graves' disease, 97
Protein synthesis
and dihydrotestosterone, 155
Pulsatile therapy
in amenorrhoea, 441

Quantitative modelling of endocrine diseases
as exemplified by diabetes, 107

Recombinant human GH
safety and biological effects of, 125

Serotoninergic control
and prolactin secretion, 601
Somatomedin-C
levels in treated and untreated acromegaly, 137
Somatostatin analogue SMS 201–995
and effective long-term treatment of acromegaly, 85
effect on pituitary GH cell adenoma, 395
Somatostatinoma
and diabetic ketoacidosis, 609
Subtotal thyroidectomy
effect on antibody activity in Graves' disease, 97
Surgery
and effect of β-endorphin infusion, 657
and bromocriptine for pituitary tumour, 541

TRH
cardiovascular and hormonal responses in acromegaly, 521
responsiveness during fasting, 9
TSH
measurement by immunochemiluminometric assay, 717
levels during short-term fasting, 9
TSH receptor antibodies
and anti-TSH antibody in Graves' disease, 311
Testicular FSH receptors
and hMG, 675
Thalamic degeneration
and lack of circadian rhythms, 573
Thyroglobulin
'fingerprint' of an individual's response to, 335
Thyroid autoantibodies
IgG subclass distribution of, 335
Thyroid function
and effect of oral frusemide, 423
Thyroid glands
acid protease activity in dieseased, 685
Thyroid microsomal antigen
'fingerprint' of an individual's response to, 335
Thyroid status
assessment using immunochemiluminometric assay of circulating TSH levels, 717
Thyroid stimulation
effects of dithiothreitol, 417
Thyroid volume
determinants of, 273
Thyroxine
binding anomaly with triiodothyronine, 565
Thyroxine binding globulin
abnormality, in Australian aborigines, 531
binding anomaly, 565

Ultrasonography
and thyroid volume, 273
Uterine cross-sectional area
and distribution of oestradiol, 581

Vasopressin
influence of nifedipine and enalapril on osmoregulation, 25
and insulin-induced hypoglycaemia, 179
Vitamine D metabolism
and hypoparathyroidism during lactation, 667